 Holly Frost
Concepts (150)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Otitis Media | 12 | 2023 | 142 | 7.420 |
Why?
| | Chlamydia Infections | 5 | 2023 | 65 | 3.770 |
Why?
| | Gonorrhea | 5 | 2023 | 54 | 3.750 |
Why?
| | Anti-Bacterial Agents | 22 | 2024 | 1484 | 3.540 |
Why?
| | Antimicrobial Stewardship | 7 | 2024 | 93 | 3.150 |
Why?
| | Conjunctivitis | 3 | 2023 | 17 | 2.490 |
Why?
| | Lyme Disease | 4 | 2018 | 32 | 1.870 |
Why?
| | Respiratory Tract Infections | 4 | 2022 | 323 | 1.820 |
Why?
| | Practice Patterns, Physicians' | 9 | 2023 | 1180 | 1.580 |
Why?
| | Acute Disease | 9 | 2023 | 914 | 1.360 |
Why?
| | Encephalitis Viruses, Tick-Borne | 2 | 2020 | 7 | 1.300 |
Why?
| | Encephalitis, Tick-Borne | 2 | 2020 | 8 | 1.290 |
Why?
| | Pharyngitis | 2 | 2018 | 23 | 1.270 |
Why?
| | Child | 28 | 2024 | 18488 | 1.250 |
Why?
| | Drug Prescriptions | 2 | 2020 | 241 | 1.150 |
Why?
| | Otitis | 2 | 2024 | 9 | 1.140 |
Why?
| | Blastomyces | 2 | 2017 | 7 | 1.100 |
Why?
| | Sinusitis | 2 | 2019 | 175 | 1.100 |
Why?
| | Blastomycosis | 2 | 2017 | 8 | 1.090 |
Why?
| | Amoxicillin | 2 | 2022 | 20 | 1.010 |
Why?
| | Chlamydia | 1 | 2023 | 10 | 0.860 |
Why?
| | Oropharyngeal Neoplasms | 1 | 2023 | 39 | 0.850 |
Why?
| | Guideline Adherence | 3 | 2022 | 497 | 0.850 |
Why?
| | Wisconsin | 5 | 2020 | 91 | 0.790 |
Why?
| | Syphilis | 1 | 2022 | 26 | 0.780 |
Why?
| | Humans | 42 | 2024 | 115587 | 0.760 |
Why?
| | Sexually Transmitted Diseases | 1 | 2023 | 154 | 0.750 |
Why?
| | Endemic Diseases | 2 | 2018 | 23 | 0.730 |
Why?
| | Bacterial Infections | 2 | 2020 | 222 | 0.720 |
Why?
| | Papillomavirus Vaccines | 1 | 2023 | 222 | 0.700 |
Why?
| | Time-to-Treatment | 1 | 2021 | 147 | 0.690 |
Why?
| | Methylprednisolone | 1 | 2020 | 83 | 0.680 |
Why?
| | Papillomavirus Infections | 1 | 2023 | 258 | 0.680 |
Why?
| | Drug-Related Side Effects and Adverse Reactions | 1 | 2022 | 242 | 0.660 |
Why?
| | Streptococcus | 1 | 2018 | 23 | 0.640 |
Why?
| | Infectious Mononucleosis | 1 | 2018 | 8 | 0.640 |
Why?
| | Anaplasmosis | 1 | 2018 | 1 | 0.630 |
Why?
| | Sexual and Gender Minorities | 1 | 2021 | 138 | 0.630 |
Why?
| | Primary Health Care | 4 | 2023 | 1518 | 0.620 |
Why?
| | Babesiosis | 1 | 2017 | 2 | 0.590 |
Why?
| | Outpatients | 4 | 2022 | 330 | 0.590 |
Why?
| | Antiprotozoal Agents | 1 | 2017 | 12 | 0.590 |
Why?
| | Chlamydia trachomatis | 3 | 2022 | 36 | 0.590 |
Why?
| | Adolescent | 12 | 2023 | 17889 | 0.580 |
Why?
| | Program Evaluation | 1 | 2021 | 836 | 0.580 |
Why?
| | Streptococcal Infections | 1 | 2018 | 132 | 0.560 |
Why?
| | Inpatients | 1 | 2020 | 380 | 0.550 |
Why?
| | Child, Preschool | 9 | 2023 | 9133 | 0.530 |
Why?
| | Antibodies, Fungal | 1 | 2015 | 9 | 0.520 |
Why?
| | Antigens, Fungal | 1 | 2015 | 28 | 0.520 |
Why?
| | Infant | 7 | 2023 | 7979 | 0.510 |
Why?
| | Rubulavirus Infections | 1 | 2013 | 2 | 0.460 |
Why?
| | Attitude of Health Personnel | 1 | 2020 | 990 | 0.420 |
Why?
| | Weight Reduction Programs | 2 | 2024 | 91 | 0.420 |
Why?
| | Retrospective Studies | 8 | 2022 | 12608 | 0.410 |
Why?
| | Pediatric Obesity | 3 | 2024 | 492 | 0.400 |
Why?
| | Genotype | 1 | 2017 | 1786 | 0.400 |
Why?
| | Physicians | 1 | 2020 | 776 | 0.390 |
Why?
| | Neisseria gonorrhoeae | 2 | 2022 | 20 | 0.390 |
Why?
| | Colorado | 4 | 2023 | 4113 | 0.380 |
Why?
| | Male | 14 | 2024 | 55949 | 0.370 |
Why?
| | Female | 14 | 2024 | 59913 | 0.350 |
Why?
| | Seroepidemiologic Studies | 2 | 2023 | 140 | 0.350 |
Why?
| | Pandemics | 3 | 2022 | 1334 | 0.340 |
Why?
| | Inappropriate Prescribing | 2 | 2021 | 52 | 0.330 |
Why?
| | Doxycycline | 2 | 2020 | 56 | 0.330 |
Why?
| | HIV Infections | 1 | 2022 | 2473 | 0.300 |
Why?
| | Antibodies, Viral | 2 | 2023 | 527 | 0.280 |
Why?
| | Drug Administration Schedule | 2 | 2020 | 724 | 0.280 |
Why?
| | Amoxicillin-Potassium Clavulanate Combination | 2 | 2022 | 8 | 0.260 |
Why?
| | Prevalence | 2 | 2023 | 2264 | 0.260 |
Why?
| | Young Adult | 4 | 2023 | 10470 | 0.260 |
Why?
| | Mass Screening | 2 | 2023 | 1024 | 0.250 |
Why?
| | Quality Improvement | 2 | 2021 | 958 | 0.230 |
Why?
| | Interrupted Time Series Analysis | 1 | 2023 | 45 | 0.220 |
Why?
| | Haemophilus influenzae | 1 | 2023 | 50 | 0.220 |
Why?
| | Nasopharynx | 1 | 2023 | 63 | 0.220 |
Why?
| | Multiplex Polymerase Chain Reaction | 1 | 2023 | 45 | 0.220 |
Why?
| | Electronic Health Records | 3 | 2024 | 805 | 0.210 |
Why?
| | Adult | 5 | 2023 | 30718 | 0.210 |
Why?
| | Age Factors | 2 | 2020 | 2907 | 0.200 |
Why?
| | Streptococcus pneumoniae | 1 | 2023 | 133 | 0.200 |
Why?
| | Ambulatory Care Facilities | 2 | 2024 | 211 | 0.200 |
Why?
| | Sexual Health | 1 | 2022 | 48 | 0.200 |
Why?
| | Pneumococcal Vaccines | 1 | 2023 | 132 | 0.200 |
Why?
| | Azithromycin | 1 | 2022 | 80 | 0.200 |
Why?
| | Focus Groups | 1 | 2023 | 393 | 0.200 |
Why?
| | Non-Randomized Controlled Trials as Topic | 1 | 2021 | 19 | 0.200 |
Why?
| | Randomized Controlled Trials as Topic | 2 | 2024 | 1216 | 0.190 |
Why?
| | Urban Health | 1 | 2021 | 75 | 0.190 |
Why?
| | Follow-Up Studies | 2 | 2022 | 4440 | 0.180 |
Why?
| | Text Messaging | 1 | 2022 | 154 | 0.180 |
Why?
| | Private Sector | 1 | 2020 | 51 | 0.170 |
Why?
| | Homosexuality, Male | 1 | 2021 | 170 | 0.170 |
Why?
| | Clinical Decision-Making | 1 | 2022 | 273 | 0.170 |
Why?
| | Drug Utilization | 1 | 2020 | 167 | 0.160 |
Why?
| | Feasibility Studies | 1 | 2021 | 741 | 0.160 |
Why?
| | Practice Patterns, Nurses' | 1 | 2018 | 15 | 0.160 |
Why?
| | Insurance, Health | 1 | 2020 | 246 | 0.150 |
Why?
| | Tick Bites | 1 | 2017 | 1 | 0.150 |
Why?
| | Babesia | 1 | 2017 | 3 | 0.150 |
Why?
| | Family Practice | 1 | 2021 | 427 | 0.150 |
Why?
| | Public Health | 1 | 2022 | 438 | 0.150 |
Why?
| | Physician Assistants | 1 | 2018 | 66 | 0.150 |
Why?
| | Interviews as Topic | 1 | 2020 | 596 | 0.150 |
Why?
| | Lung Diseases, Fungal | 1 | 2017 | 13 | 0.140 |
Why?
| | Bacteria | 1 | 2023 | 729 | 0.140 |
Why?
| | Nurse Practitioners | 1 | 2018 | 105 | 0.140 |
Why?
| | Pediatricians | 1 | 2018 | 125 | 0.140 |
Why?
| | Physicians, Family | 1 | 2018 | 201 | 0.140 |
Why?
| | Delayed Diagnosis | 1 | 2017 | 71 | 0.140 |
Why?
| | Ambulatory Care | 1 | 2020 | 478 | 0.140 |
Why?
| | Internal Medicine | 1 | 2018 | 211 | 0.140 |
Why?
| | Immunoglobulin M | 1 | 2017 | 254 | 0.130 |
Why?
| | Reproducibility of Results | 1 | 2023 | 2800 | 0.130 |
Why?
| | Ticks | 1 | 2015 | 12 | 0.130 |
Why?
| | Immunologic Tests | 1 | 2015 | 16 | 0.130 |
Why?
| | Disease Reservoirs | 1 | 2015 | 19 | 0.130 |
Why?
| | United States | 3 | 2022 | 12295 | 0.130 |
Why?
| | Emergency Medicine | 1 | 2018 | 227 | 0.130 |
Why?
| | Vaccination | 1 | 2023 | 1209 | 0.120 |
Why?
| | Antifungal Agents | 1 | 2015 | 133 | 0.120 |
Why?
| | Parainfluenza Virus 4, Human | 1 | 2013 | 2 | 0.120 |
Why?
| | Pediatrics | 1 | 2021 | 986 | 0.110 |
Why?
| | Immunoglobulin G | 1 | 2017 | 781 | 0.110 |
Why?
| | Seasons | 1 | 2015 | 449 | 0.110 |
Why?
| | Incidence | 1 | 2018 | 2335 | 0.100 |
Why?
| | Cohort Studies | 1 | 2021 | 4944 | 0.100 |
Why?
| | Sensitivity and Specificity | 1 | 2015 | 1718 | 0.090 |
Why?
| | Practice Guidelines as Topic | 1 | 2018 | 1405 | 0.090 |
Why?
| | Ecosystem | 1 | 2015 | 526 | 0.090 |
Why?
| | Prospective Studies | 1 | 2022 | 6264 | 0.090 |
Why?
| | Aged | 2 | 2017 | 19251 | 0.080 |
Why?
| | Emergency Service, Hospital | 1 | 2020 | 1829 | 0.080 |
Why?
| | Treatment Outcome | 1 | 2022 | 9159 | 0.080 |
Why?
| | Disease Progression | 1 | 2015 | 2418 | 0.080 |
Why?
| | Infant, Newborn | 1 | 2018 | 5077 | 0.080 |
Why?
| | Middle Aged | 2 | 2017 | 26999 | 0.070 |
Why?
| | Health Promotion | 2 | 2023 | 693 | 0.070 |
Why?
| | Cross-Sectional Studies | 1 | 2017 | 4435 | 0.070 |
Why?
| | Aged, 80 and over | 1 | 2017 | 6417 | 0.070 |
Why?
| | Hospitals, General | 1 | 2024 | 19 | 0.060 |
Why?
| | Risk Factors | 1 | 2017 | 8697 | 0.060 |
Why?
| | Benchmarking | 1 | 2024 | 163 | 0.050 |
Why?
| | Reproductive Health | 1 | 2022 | 70 | 0.050 |
Why?
| | Educational Status | 1 | 2023 | 413 | 0.050 |
Why?
| | Sexual Behavior | 1 | 2022 | 440 | 0.040 |
Why?
| | Poverty | 1 | 2021 | 448 | 0.040 |
Why?
| | Body Mass Index | 1 | 2024 | 1971 | 0.030 |
Why?
| | Animals | 1 | 2015 | 32102 | 0.030 |
Why?
|
|
Frost's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|